TY  - JOUR
PY  - 2013//
TI  - Determination of burn patient outcome by large-scale quantitative discovery proteomics
JO  - Critical care medicine
A1  - Finnerty, Celeste C.
A1  - Jeschke, Marc G.
A1  - Qian, Wei-Jun
A1  - Kaushal, Amit
A1  - Xiao, Wenzhong
A1  - Liu, Tao
A1  - Gritsenko, Marina A.
A1  - Moore, Ronald J.
A1  - Camp, David G.
A1  - Moldawer, Lyle L.
A1  - Elson, Constance
A1  - Schoenfeld, David
A1  - Gamelli, Richard
A1  - Gibran, Nicole S.
A1  - Klein, Matthew
A1  - Arnoldo, Brett D.
A1  - Remick, Daniel
A1  - Smith, Richard D.
A1  - Davis, Ronald
A1  - Tompkins, Ronald G.
A1  - Herndon, David N.
SP  - 1421
EP  - 1434
VL  - 41
IS  - 6
N2  - OBJECTIVES:: Emerging proteomics techniques can be used to establish proteomic outcome signatures and to identify candidate biomarkers for survival following traumatic injury. We applied high-resolution liquid chromatography-mass spectrometry and multiplex cytokine analysis to profile the plasma proteome of survivors and nonsurvivors of massive burn injury to determine the proteomic survival signature following a major burn injury. DESIGN:: Proteomic discovery study. SETTING:: Five burn hospitals across the United States. PATIENTS:: Thirty-two burn patients (16 nonsurvivors and 16 survivors), 19-89 years old, were admitted within 96 hours of injury to the participating hospitals with burns covering more than 20% of the total body surface area and required at least one surgical intervention. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: We found differences in circulating levels of 43 proteins involved in the acute-phase response, hepatic signaling, the complement cascade, inflammation, and insulin resistance. Thirty-two of the proteins identified were not previously known to play a role in the response to burn. Interleukin-4, interleukin-8, granulocyte macrophage colony-stimulating factor, monocyte chemotactic protein-1, and β2-microglobulin correlated well with survival and may serve as clinical biomarkers. CONCLUSIONS:: These results demonstrate the utility of these techniques for establishing proteomic survival signatures and for use as a discovery tool to identify candidate biomarkers for survival. This is the first clinical application of a high-throughput, large-scale liquid chromatography-mass spectrometry-based quantitative plasma proteomic approach for biomarker discovery for the prediction of patient outcome following burn, trauma, or critical illness.<p />  <p>Language: en</p>
LA  - en
SN  - 0090-3493
UR  - http://dx.doi.org/10.1097/CCM.0b013e31827c072e
ID  - ref1
ER  -